Loading
Sequencing of 373 endometrial cancers revealed four molecular groups, POLE ultramutated, microsatellite unstable, copy-number low and copy-number high, that cut across the traditional endometrioid and serous types and predict outcome.
Integrated genomic, transcriptomic and proteomic analysis of 373 endometrial carcinomas by The Cancer Genome Atlas defining four groups: POLE ultramutated (with excellent outcome), microsatellite instability hypermutated, copy-number low (endometrioid) and copy-number high (serous-like, TP53-mutated, worst outcome); about a quarter of high-grade endometrioid tumours resembled serous carcinoma molecularly.
This is the origin of the molecular classification now used for every endometrial cancer, translated into a practical test by ProMisE.
Shares POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma.
Shares POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma.
Shares POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma.
Shares POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma.
Shares POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma.
Shares POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma.
Shares POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma.